Our preference goes for MCT1 because (i) it is expressed in oxidative cancer cells located at the vicinity of functional blood vessels delivering systemic treatments, and (ii) as a target it would offer anticancer selectivity by corrupting the metabolic symbiosis between glycolytic and oxidative cancer cells. The gene discussed is SLC16A1; the disease is cancer.